Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy

NCT03750240 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT03750240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03750240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy
Lead sponsor
NYU Langone Health
Phase
Not applicable
Overall status
Terminated
Start date
July 25, 2017
Completion date
June 24, 2021
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, triple negative breast cancer